Establishment of an in vivo cell differentiation method that induces an undifferentiated human corneal endothelial subpopulation to mature corneal endothelial cells
Project/Area Number |
17K11461
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Ophthalmology
|
Research Institution | Kyoto Prefectural University of Medicine |
Principal Investigator |
Toda Munetoyo 京都府立医科大学, 医学(系)研究科(研究院), 特任助教 (30550727)
|
Project Period (FY) |
2017-04-01 – 2020-03-31
|
Project Status |
Completed (Fiscal Year 2019)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000)
Fiscal Year 2018: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2017: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | 角膜内皮細胞 / 再生医療 / 移植・再生医療 |
Outline of Final Research Achievements |
In this present study, we successfully established a modified cell expansion method that increases the efficiency of expanding an undifferentiated human corneal endothelial cell (CEC) subpopulation to approximately 1.5 times higher than the previously used method by suppressing the stratification of the cells and the changes to a fibroblast-like morphology. Our novel method successfully expands an undifferentiated human CEC subpopulation by approximately 10,000 times over a 5-week period. Moreover, we found that pretreatment with specific functional low-molecular-weight compounds used for the induction of the differentiation of pluripotent differentiated CECs increases the efficiency of those cells to differentiate to mature CECs. These findings allowed us to successfully establish a cell differentiation method that induces an undifferentiated human CEC subpopulation to mature CECs at an efficiency of approximately 85%.
|
Academic Significance and Societal Importance of the Research Achievements |
一眼から100人水準の増幅であった治験時製法に比べ大幅に増幅効率が改善された。本技術の応用により、Fuchs 角膜ジストロフィー患者を含む300万人以上の潜在患者への適用が可能となり、本邦が世界をリードする革新的角膜移植術である「培養ヒト角膜内皮細胞前房内注入療法」を世界的なレベルにまで発展させることができると期待できる。
|
Report
(4 results)
Research Products
(5 results)